Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
CDT Equity Inc. has filed a certificate of amendment to effectuate a 1-for-20 reverse stock split of its common stock, effective November 5, 2026. The split is intended to maintain compliance with Nasdaq Listing Rules, reducing the outstanding share count from approximately 20.4 million to 1.0 million shares. Trading on a split-adjusted basis is expected to begin on November 6, 2026, under the existing ticker symbol 'CDT'.
Jasper Therapeutics announced a 1-for-30 reverse stock split of its common stock, effective November 6, 2026. The split will reduce the number of outstanding shares from approximately 33.3 million to 1.1 million to increase the per-share trading price on the Nasdaq Capital Market. The authorized number of shares remains unchanged at 490 million, resulting in an increase in authorized but unissued shares available for future use.
Bluejay Diagnostics implemented a 1-for-4 reverse stock split of its common stock, effective November 3, 2026. The split reduces the number of outstanding shares from approximately 4.47 million to 1.12 million to maintain compliance with Nasdaq listing requirements. Trading will continue under the ticker 'BJDX' with a new CUSIP number.
ProShares Trust II announced a 1-for-2 reverse stock split for the ProShares VIX Mid-Term Futures ETF (VIXM), effective November 19, 2026. The split is part of a broader action by ProShares involving forward and reverse splits across 15 different ETFs to adjust share prices without changing total investment value. Fractional shares resulting from the reverse split will be redeemed for cash.
Enhanced Group Inc. has filed a Certificate of Amendment to its Charter to effect a 1-for-10 reverse stock split of its Class A and Class B common stock. Additionally, the company entered into amendments to Transaction Support Agreements with its CEO and controlling shareholders to extend lock-up restrictions, eliminating a scheduled six-month partial release in favor of a full twelve-month lock-up period.
22nd Century Group announced a 1-for-58 reverse stock split of its common stock, effective November 5, 2026. The action is intended to restore compliance with the Nasdaq Capital Market's minimum bid price requirement for continued listing. Shares will begin trading on a split-adjusted basis under a new CUSIP number while maintaining the ticker symbol 'XXII'.
iSpecimen Inc. stockholders approved an amendment to the company's Certificate of Incorporation to effect a reverse stock split. The approved ratio range is between 1-for-10 and 1-for-100, with the final ratio to be determined by the Board of Directors.
NextNRG, Inc. is implementing a 1-for-10 reverse stock split of its common stock, effective October 30, 2026. The split will reduce the number of outstanding shares from approximately 16.84 million to 1.68 million and reduce authorized shares from 500 million to 50 million. The action is intended to consolidate shares and will result in the stock trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol NXXT.
MariMed stockholders approved a proposal to authorize the board of directors to effect a reverse stock split of its common stock at a ratio between 1-for-50 and 1-for-100. The board retains the discretion to determine the final ratio and timing, or to abandon the split entirely, with the primary goal of potentially meeting listing requirements for a U.S. national securities exchange.
Glucotrack, Inc. implemented a 1-for-2 reverse stock split of its common stock effective October 23, 2026. The split reduced the number of outstanding shares from approximately 2.37 million to 1.18 million to satisfy Nasdaq listing requirements. The company's common stock began trading on a split-adjusted basis on October 26, 2026.
Patriot Gold Corp. announced that its board and majority stockholders have approved a 1-for-10 reverse stock split of its issued and outstanding common stock. The split is currently undergoing regulatory review by FINRA and the Canadian Securities Exchange (CSE), with the effective date and split-adjusted trading date yet to be established.
Healthcare Triangle, Inc. effected a 1-for-20 reverse stock split of its common stock effective October 26, 2026. The action reduced the number of outstanding shares from approximately 17.7 million to 886,587 to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
GeoVax Labs stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-10 and 1-for-25. Additionally, shareholders approved the issuance of up to 11.4 million shares related to a warrant exercise inducement from August 2026.
aTyr Pharma filed a Certificate of Amendment to effect a 1-for-40 reverse stock split of its common stock, effective October 28, 2026. The split will reduce the number of outstanding shares from approximately 100.5 million to 2.5 million to meet exchange requirements. Trading on a split-adjusted basis will begin on The Nasdaq Capital Market on October 29, 2026.
Envoy Medical implemented a 1-for-10 reverse stock split of its Class A common stock, effective October 26, 2026. The split is intended to regain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. Every 10 shares of outstanding common stock were automatically combined into one share, with fractional shares settled in cash.
Onconetix, Inc. announced a 1-for-10 reverse stock split of its common stock, effective November 6, 2026. This follows a previous 1-for-10 split in May 2026, resulting in a cumulative 1-for-100 consolidation to reduce outstanding shares from approximately 5.9 million to 589,000. The action is intended to adjust the per-share trading price on the Nasdaq Capital Market.
Fold Holdings stockholders approved a proposal to authorize the Board of Directors to effect a reverse stock split of the company's common stock at a ratio between 1-for-2 and 1-for-50. The final decision on the exact ratio and timing remains at the discretion of the Board following this approval.
Silexion Therapeutics Corp shareholders approved a 1-for-24 reverse stock split of the company's ordinary shares, increasing the par value from $0.135 to $3.24 per share. Additionally, shareholders approved an increase in authorized share capital from 15.9 million to 515.9 million ordinary shares. The reverse split and capital increase were finalized at a reconvened extraordinary general meeting on October 26, 2026.
Adagio Medical Holdings stockholders approved a proposal for a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-500. The final ratio will be determined by the Board of Directors at its discretion to consolidate outstanding shares.
Healthcare Triangle stockholders approved a proposal to authorize the Board of Directors to effect one or more reverse stock splits at a ratio ranging from 1-for-2 to 1-for-25. Additionally, shareholders approved an amendment to the 2020 Stock Incentive Plan and authorized potential share issuances exceeding 20% of outstanding stock at below-market prices for Nasdaq compliance purposes.
Canopy Growth shareholders approved a special resolution at the 2026 Annual General and Special Meeting to authorize a reverse stock split. The Board has the discretion to consolidate common and exchangeable shares at a ratio between 1-for-5 and 1-for-15 at any time prior to September 25, 2027.
Nuwellis, Inc. has announced a 1-for-9 reverse stock split of its issued and outstanding common stock, effective October 26, 2026. The split-adjusted shares will begin trading on the Nasdaq Capital Market under the existing symbol 'NUWE' on October 27, 2026. This action consolidates every nine shares into one share to adjust the company's capital structure.
Glucotrack, Inc. announced a 1-for-2 reverse stock split of its common stock effective October 26, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split will reduce the outstanding share count from approximately 2.37 million to 1.18 million shares. Separately, the company raised $2.0 million in gross proceeds through the issuance of senior secured convertible promissory notes and warrants.
Banzai International, Inc. announced a 1-for-10 reverse stock split of its Class A and Class B common stock, effective October 27, 2026, to maintain compliance with Nasdaq's minimum bid price requirement. Concurrent with the split, the company is changing its legal name to Parabolic Technologies, Inc. The split will reduce the outstanding Class A shares from approximately 5.06 million to 506,121.
Blaize Holdings declared a dividend of Series B Preferred Stock to common stockholders to facilitate a potential reverse stock split. The Series B shares carry 1,000,000 votes each and vote with common stock exclusively on reverse split and related adjournment proposals. This mechanism is designed to ensure the company can meet voting requirements to consolidate shares and maintain its Nasdaq listing.
Azitra, Inc. has filed a certificate of amendment to effectuate a 1-for-10 reverse stock split of its common stock, effective October 26, 2026. The split aims to consolidate every 10 shares into one share to adjust the trading price on the NYSE American. No fractional shares will be issued, with stockholders receiving cash payments in lieu of fractional interests.
Capstone Holding Corp. implemented a 1-for-30 reverse stock split of its common stock, effective October 19, 2026. The consolidation reduced the outstanding share count from approximately 27.5 million to approximately 0.9 million shares to adjust the trading price on the Nasdaq Capital Market. No fractional shares were issued, with stockholders receiving cash in lieu of fractional interests based on a $2.72 closing price.
Nightfood Holdings, Inc. effected a 1-for-150 reverse stock split of its common stock effective October 20, 2026. The split reduced the outstanding share count from approximately 543.9 million to 3.6 million shares to increase the per-share price in support of a proposed Nasdaq Capital Market uplisting.
Moleculin Biotech announced a 1-for-20 reverse stock split of its common stock, effective October 20, 2026. The split will reduce the number of outstanding shares from approximately 20.91 million to approximately 1.05 million to satisfy Nasdaq listing requirements. The company's common stock will continue to trade under the ticker 'MBRX' with a new CUSIP number.
Enhanced Group Inc. announced a one-for-ten reverse stock split of its Class A and Class B common stock, effective October 29, 2026. The split is intended to consolidate every ten shares into one share to adjust the trading price on the NYSE, with no fractional shares being issued. The action follows a definitive information statement filed earlier in the month and complies with NYSE advance notice requirements.